Patents by Inventor Manish Kohli

Manish Kohli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine
    Patent number: 10982286
    Abstract: The present invention relates to methods of using cell-free DNA analysis for guiding treatment of advanced prostate cancer. In particular, liquid biopsies are collected from urine and/or plasma of patients for measuring copy number variation in cell-free DNA associated with metastatic prostate cancer. In particular, urine genomic abnormality (UGA) and plasma genomic abnormality (PGA) values are contemplated for use in predicting treatment responses in advanced prostate cancer patients and for use in making decisions related to androgen deprivation therapy (ADT) treatment outcomes in hormone sensitive stage and for starting or changing chemotherapy treatments in castrate resistant advanced cancer stage.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: April 20, 2021
    Assignees: Mayo Foundation for Medical Education and Research, The Medical College of Wisconsin, Inc., UWM Research Foundation, Inc.
    Inventors: Manish Kohli, Liang Wang, Chiang-Ching Huang
  • Algorithmic Approach for Determining the Plasma Genome Abnormality PGA and the Urine genome abnormality UGA scores based on Cell Free cfDNA Copy Number Variations in Plasma and Urine.
    Publication number: 20170211153
    Abstract: The present invention relates to methods of using cell-free DNA analysis for guiding treatment of advanced prostate cancer. In particular, liquid biopsies are collected from urine and/or plasma of patients for measuring copy number variation in cell-free DNA associated with metastatic prostate cancer. In particular, urine genomic abnormality (UGA) and plasma genomic abnormality (PGA) values are contemplated for use in predicting treatment responses in advanced prostate cancer patients and for use in making decisions related to androgen deprivation therapy (ADT) treatment outcomes in hormone sensitive stage and for starting or changing chemotherapy treatments in castrate resistant advanced cancer stage.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 27, 2017
    Inventors: Manish Kohli, Lang Wang, Chiang-Ching Huang
  • PREDICTING RESPONSES TO ANDROGEN DEPRIVATION THERAPY
    Publication number: 20130171647
    Abstract: This document provides methods and materials for identifying prostate cancer patients likely to respond to an androgen deprivation therapy. For example, methods and materials for identifying a prostate cancer patient likely to respond to an androgen deprivation therapy based at least in part on the presence of a genetic variation in a TMRT11 nucleic acid are provided. This document also provides methods and materials for identifying prostate cancer patients likely to survive prostate cancer related death for a short or long period of time. For example, methods and materials for identifying a prostate cancer patient likely to survive prostate cancer related death for a short or long period of time based at least in part on the presence of a genetic variation in a UGT1A3 nucleic acid, a UGT1A7 nucleic acid, and/or a UGT1A10 nucleic acid are provided.
    Type: Application
    Filed: September 8, 2011
    Publication date: July 4, 2013
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Douglas W. Mahoney, Manish Kohli, James R. Cerhan, Steven M. Offer